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Abstract
Introduction: Intraarticular hyaluronan (HA) is used clinically for symptomatic relief in patients with knee
osteoarthritis (OA); however, the mechanism of action is unclear. In this study, we examined the effects of a single
injection of HA on joint tissue pathology, mechanical allodynia and gait changes (measured by stride times) in a
murine model of OA.
Methods: OA was induced in the right knee joint (stifle) of 12-week-old male C57BL/6 mice by transforming
growth factor b1 (TGFb1) injection and treadmill running for 14 days. Gait parameters were quantified by using
TreadScan, mechanical allodynia was evaluated with von Frey filaments, and joint pathology was evaluated by
scoring of macroscopic images for both cartilage erosion and periarticular fibrosis. HA or saline control was
injected 1 day after TGFb1 injection but before the start of treadmill running.
Results: OA development in this model was accompanied by significant (P < 0.01) enhancement of the stance and
propulsion times of affected legs. HA injection (but not saline injection) blocked all gait changes and also protected
joints from femoral cartilage erosion as well as tibial and femoral tissue fibrosis. Both HA injection and saline injection
attenuated acute allodynia, but the HA effect was more pronounced and prolonged than the saline injection.
Conclusions: We conclude that videographic gait analysis is an objective, sensitive and reproducible means of
monitoring joint pathology in experimental murine OA, since stance time appears to correlate directly with OA
severity. A single injection of HA prevents acute and prolonged gait changes and ameliorates the cartilage erosion
and periarticular fibrosis normally seen in this model. We speculate that the capacity of HA to prevent cartilage
erosion results from its normalization of joint biomechanics and its inhibitory effects on periarticular cells, which are
involved in tissue hyperplasia and fibrosis. This effect of exogenous HA appears to mimic the protective effects of
ablation of Adamts5 (a disintegrin and metalloproteinase with thrombospondin motifs 5) on experimental murine
OA, and we speculate that a common mechanism is involved.
Introduction
Progressive osteoarthritis (OA) of the knee is character-
ized by synovial inflammation, cartilage erosion, soft tis-
sue fibrosis and subchondral bone sclerosis as well as
pain and stiffness in the affected joints [1]. One widely
used therapy for symptomatic relief of pain and stiffness
is the intraarticular injection of hyaluronan (HA). A
meta-analysis of clinical trials in which an aggregate
total of 18 different commercial HA preparations were
used summarized the results as “generally supporting
the use of HA in the treatment of OA” [2] (page 3).
Overall, the aforementioned analyses support the use of
the HA class of products in the treatment of knee OA.
In a second meta-analysis [3], the conclusion was that
HA injection led to a modest improvement in symp-
toms, including pain, relative to placebo. The variability
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the different evaluation scales used (for example, the
Western Ontario and McMaster Universities Osteoar-
thritis Index [4] and the Knee Injury and Osteoarthritis
Outcome Score [5]) or to the finding that pain improve-
ment with HA appears to be confined to individuals
older than about 60 years of age [6].
In addition to potential symptomatic relief, there is
ample evidence for statistically significant disease-modi-
fying effects of intraarticular HA injection in both ani-
mal models and human OA [7]. For example, in rat and
rabbit OA models, HA has been found to block inflam-
mation and chondrocyte apoptosis and to prevent carti-
lage degeneration [8-10]. In the canine anterior cruciate
ligament transection model [11], HA inhibited the for-
mation of a fibroblast-like cell layer on the articular sur-
face, reduced cartilage lesions and significantly improved
both gross joint morphology and histopathology. In
both canine and ovine OA models, subintimal fibrosis
and hypervascularity of the synovium was reduced after
intraarticular HA injection [12,13]. The clinical rele-
vance of such observations is underscored by reports of
human OA in which HA has been found to reconstitute
the superficial cartilage layer [14], reduce synovial
inflammation and edema [15] and reduce the number
and aggregation of lining synoviocytes [16], as well as to
reduce the progression of joint space narrowing in
patients with high joint space width upon entry into the
study [17]. Although the cell biological mechanisms
underlying the action of HA in both animal models and
human OA are poorly understood, the capacity of HA
to inhibit aberrant tissue remodeling in the joint appears
to be related to its efficacy in postsurgical repair in
other tissues and organs. For example, ocular, thoracic
and plastic surgery all involve the use of HA to optimize
tissue restoration and minimize scarring [18,19], and
HA is also used to prevent postoperative peritoneal and
intrauterine adhesions [20,21].
The overall objective in the current work was to
examine the effect of intraarticular HA injection on
well-defined stages of the initiation and progression of
murine OA. We have utilized a nonsurgical murine
model of OA [22] which has a highly reproducible dis-
ease course leading to overt pathology in 3 weeks. In
addition to performing macroscopic and microscopic
evaluations of joint tissue structure, we determined
mechanical allodynia (pain caused by stimuli that do not
normally evoke pain [23]) and locomotive function of
the hindlimbs by using the TreadScan™ gait analysis
system (CleverSys Inc., Reston, VA, USA). We describe
statistically robust changes in gait parameters during the
different phases of OA development and show ameliora-
tive effects of HA injection. In brief, our data show that
a single injection of HA during the early transforming
growth factor b1( T G F b1)-induced inflammatory phase
of the model prevents both acute and long-term gait
changes. In addition, the normalization of gait by HA
injection is accompanied by a marked reduction in both
cartilage erosion and intraarticular soft tissue fibrosis.
Materials and methods
Hyaluronan preparation
HA (Durolane; Smith & Nephew Inc., London, UK) was
prepared from purified staphylococcal HA at Q-Med
AB, Uppsala, Sweden. Briefly, HA is dispersed in solu-
tion and cross-linked via hydroxyl groups with butane-
diol diglycidyl ether. About one cross-link is formed per
100 disaccharides, and the final HA concentration is 20
μg/ml. Ten microliters of HA (75% vol/vol in saline, pH
6.8) were injected through the patellar ligament into the
joint space using an insulin syringe fitted with a 30-
gauge needle. The accuracy of the injection procedure
for HA was verified with untreated mice (n =6 )u s i n g
an HA/India ink solution (10:1 vol/vol) for injection,
and accurate delivery was verified by the presence of the
dye exclusively in the synovial cavity on dissection.
Osteoarthritis model
Male mice (C57BL/6, age 12 weeks) were bred in-house,
and all animal protocols were approved by the Rush
University Medical Center Animal Care Committee. OA
was induced as described previously [22]. Briefly, the
procedure involves unilateral intraarticular injection of
active TGFb1 (200 ng in 0.1% (wt/vol) bovine serum
albumin) at 0 and 48 hours, followed by daily enforced
uphill treadmill running (17° gradient at 32 cm/second
for 20 minutes) for 2 weeks.
Experimental groups and number of mice examined
Four experimental groups were used according to the
timed events illustrated in Figure 1: (1) The OA-only
group (n = 14) received TGFb1 injections at days 1 and
3, followed by daily treadmill running between days 5
and 19; (2) the OA + HA group (n = 14) received
TGFb1 injections at days 1 and 3 and an HA injection
at day 4, followed by daily treadmill running between
days 5 and 19; (3) the OA + saline group (n =8 )
received TGFb1i n j e c t i o n sa td a y s1a n d3a n das a l i n e
injection at day 4, followed by daily treadmill running
between days 5 and 19; and (4) the treadmill-only group
(n = 12) were subjected to daily treadmill running
between days 5 and 19.
Gait measurement using TreadScan
Gait analysis was done using TreadScan at the time
points indicated in Figure 1. The treadmill and TreadS-
can equipment were housed in a designated light- and
temperature-controlled room. Gait measurements were
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day and were carried out by the same individual
throughout the study. TreadScan data on each mouse
were acquired for about 20 seconds of fast walking at 18
cm/second at a 17° uphill gradient. This configuration
represented optimal conditions for achieving continuous
walking and more regular stride times for the C57BL/6
mouse strain used in this study. The recorded walking
activity was analyzed using TreadScan version 3.0 soft-
ware, which calculates the mean value for 37 locomo-
tion parameters for each mouse from about 1,500 high-
quality video frames. For the present study, data analysis
was restricted to the components of the stride cycle for
the hindfeet. The stride cycle represents the sum of the
s t a n c ea n ds w i n gt i m e s .T h es t a n c et i m ef o rah i n d f o o t
is the elapsed period between the first contact ("heel
strike”) and the last contact ("liftoff”) with the surface
a n di st h es u mo fb r a k ea n dp r o p u l s i o nt i m e s .T h e
brake time is the elapsed period between heel strike and
the instant at which the foot reaches a position which is
80% of the distance from the front to the rear of the
mouse (excluding the tail). This position represents the
normal still stance position for mice. The propulsion
time is the stance time minus the brake time. Presently,
TreadScan does not directly evaluate loading through
force plates as is done routinely in large animal studies
[24] and human gait studies [25].
Mechanical allodynia
Mechanical allodynia was determined by using von Frey
filaments as described previously [23], with each 50%
withdrawal threshold value (measured in grams) calcu-
lated as the average of three sequential measurements
made at 5-minute intervals. Measurements were taken
by the same individual for all mice and were done
before treadmill running on any particular day as indi-
cated in the schematic in Figure 1. A separate set of
mice (n = 8) for each treatment group was used for
measurement of mechanical allodynia only.
Joint pathology
Macroscopic cartilage erosion and fibrosis scoring was
done essentially as describedp r e v i o u s l y[ 2 2 ]w i t ht h e
inclusion of patellar groove analysis. On day 19, right
(injected) knee joints were carefully opened and menisci
were removed, and after rinsing them with phosphate-
buffered saline, India ink was applied to all articular sur-
faces with a small paint brush, and then they were
rinsed again. Surfaces were photographed under a
Nikon dissecting microscope (SMZ1000) (Melville, NY,
USA) at sixfold magnification and images were pro-
cessed using SPOT Basic imaging software (Diagnostic
Instruments, Inc., Sterling Heights, MI, USA) at 32-fold
magnification. For each joint, cartilage erosion scoring
was carried out with the investigator blinded to sample
identity. The twelve areas scored were the proximal and
distal regions of the lateral and medial patellar grooves,
the anterior and posterior regions of the lateral and
medial femoral condyles and the anterior and posterior
regions of the lateral and medial tibial plateaus. Scores
(1 through 8) for each of the twelve areas were based on
a visual estimate of the percentage of the specific carti-
lage surface affected by lesions, where a score of 8 was
equivalent to 100%. Individual joint data were calculated
for the patellar groove (32 maximum), the femoral con-
dyle (32 maximum) and the tibial plateau (32 maxi-
mum) areas separately. In OA joints, macroscopic
fibrosis developed at one or more of six locations. These
were the posterior half of the medial and lateral tibial
plateaus, the anterior half of the medial and lateral
femoral condyles and the distal half of the medial and
lateral patellar groove. In each location, fibrosis
appeared as a variably sized whitish rim to the articular
surface. Scores (0 through 3) were done with the investi-
gator blinded to sample identity and were based on a
visual estimate of the area of the lesion relative to the
area (set arbitrarily at 10) of the respective articular sur-
face. A score of 3 (maximum observed) corresponded to
a lesion with an area equivalent to about 30% of the
total area being scored. Individual joint fibrosis data
were calculated separately for the medial and lateral
anterior femoral condyles (6 maximum), the distal med-
ial and distal lateral patellar groove (6 maximum) and
the posterior lateral and medial tibial plateaux (6
maximum).
Histology and immunohistochemistry
Following macroscopic evaluation, femoral joints were
placed intact in 10% neutral buffered formalin for 48
hours, decalcified in 0.5 M ethylenediaminetetraacetic
acid for 14 days, processed and embedded in paraffin.
Whole joint sagittal sections (5 μm) were obtained from
approximately 10 equidistant locations spanning the
entire lateral and medial compartments. Sections were
Figure 1 Schematic showing the experimental protocol.T h e
schematic provides details of the time line used for joint injections,
treadmill running and data collection. See Materials and methods
for full description.
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For immunohistochemistry, sections were treated with
proteinase K (5 mg/ml at 37°C for 30 minutes; Sigma-
Aldrich St. Louis, MO, USA) for epitope retrieval prior
to primary antibody incubation. The type I collagen-spe-
cific antibody (ab34710; Abcam, Cambridge, MA, USA)
was used at 10 μg/ml with incubation for 1 hour. The
secondary antibody was peroxidase-coupled goat anti-
rabbit immunoglobulin G (IgG). Preimmune rabbit IgG
was used as a first antibody control.
Data normalization and statistical analysis
Gait analyses in pilot studies using this OA model
showed that a statistical power >80% can be achieved
with 10 mice per group. In the study reported here, the
value (expressed in milliseconds) for each gait parameter
(on days 5, 12 and 19) in each hindlimb of each mouse
was normalized to the corresponding pretreatment value
for that mouse. This was done to minimize animal var-
iation, which, on a weight basis, ranged from approxi-
mately 23 g to 26 g. The significance of the difference
between the mean (±SD) of the normalized values and
unity was determined by using an unpaired Student’s t-
test and a signed two-tailed Wilcoxon rank-sum test.
The allodynia data (in grams) are the means of the 50%
withdrawal threshold values for each group at each time
point, and the significance of the difference between
treatment groups was determined by using Student’s t-
test only. For both statistical tests, P values < 0.05 were
considered statistically significant.
Results
Induction of murine OA causes an acute and prolonged
increase in stance and propulsion times, and intraarticular
HA injection prevents these gait changes
A typical set of data (expressed in milliseconds) for
stance, swing, propulsion and brake times for a repre-
sentative mouse from each of the three experimental
groups (OA, OA + HA and OA + saline) is shown in
Figure 2. Inclusion of data for a treadmill-only mouse
illustrates that there was no major change from baseline
(pretreatment) values at any time. For this mouse (at all
times), the percentage stance time (percentage of total
s t r i d et i m ew h e r es t r i d et i m e=s t a n c et i m e+s w i n g
time) was about 48% (composed of approximately 26%
brake time and about 22% propulsion time), and the
percentage swing time was 52%. In the OA mouse, the
total stride time (stance time + swing time = approxi-
mately 280 milliseconds) was not markedly changed
over the course of the experiment; however, alterations
in individual percentage stance time, propulsion and
swing times were detected as early as day 5, and these
Figure 2 Gait data for a representative mouse from each experimental group. Gait data are shown in milliseconds for stance, brake,
propulsion and swing times in each of the four experimental groups. Typical results from a single mouse are shown for the osteoarthritis (OA)
group (diamonds), the OA + hyaluronan (HA) group (circles), the OA + saline group (squares) and the treadmill-only group (triangles).
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the percentage stance time increased from about 48% at
baseline to approximately 75% at day 19, and this was
almost entirely due to the increase in the propulsion
percentage (from about 22% to approximately 47%).
Accordingly, the percentage swing time decreased from
approximately 53% at baseline to about 32% at day 19.
The major increase in stance time (absolute value and
as a percentage of stride) in the OA group was not due
to a slower walking speed, since this was set at 18 cm/
second on the TreadScan treadmill. Data (not shown)
on stride length (expressed in centimeters) and stride
frequency (expressed in Hertz) did not clearly indicate
whether the OA mice changed the length and/or the
frequency of strides. For the mouse from the OA + HA
group (Figure 2), the total stride time was also essen-
tially constant at approximately 280 milliseconds
throughout, and there were no marked changes in indi-
vidual parameters from baseline at any time. This
showed that for this mouse, the HA injection had
entirely prevented the OA-associated gait changes.
Importantly, the effect of HA on gait was not simply
due to a washout effect or a dilution of the joint fluid,
since saline injection instead of HA did not block the
alteration in gait parameters seen with development of
OA (see OA + saline data) (Figure 2).
Next, a statistically powered study was done on the
three experimental groups: for OA (n =1 4 ) ,O A+H A
(n = 14) and OA + saline (n = 8). The gait data for the
affected (injected) limbs from the three groups at days
5, 12 and 19 are shown in Table 1. We present only the
normalized stance and propulsion data, since in all
groups and for both legs the brake time and total stride
time were not statistically different from pretreatment
values. Considering the means of the normalized data, it
is clear that the increase over unity in stance time in the
OA group (1.18, 1.40 and 1.43-fold (means ± SD) on
days 5, 12 and 19, respectively) was essentially elimi-
nated by injection of HA (1.05, 1.10 and 0.99-fold
change (means ± SD) on days 5, 12 and 19, respec-
tively). On the other hand, with injected saline the
equivalent data (1.29, 1.24 and 1.32 -fold increase
(means ± SD)) were not markedly altered from the OA
values. The equivalent figures for the propulsion times
in the OA group (1.46, 1.28 and 1.61 -fold increase
(means ± SD)), the OA + HA group (1.19, 1.26 and 0.94
-fold increase (means ± SD)) and the OA + saline group
(1.78, 1.16 and 1.55 -fold increase(means ± SD)) con-
firmed the overall inhibitory effect of HA on gait
changes and the lack of an effect with saline.
To examine the possibility of compensatory gait changes
in the contralateral limbs, we also analyzed the stance and
propulsion times in the contralateral legs for the same
mice (Table 2). This showed that there was essentially no
statistically significant change from pretreatment values in
either parameter for any treatment group on days 5, 12
and 19. The only exceptions were a reduction in propul-
sion time for the OA + HA group at day 5 and an increase
in stance time in the OA + saline group at day 12; how-
ever, these effects were not further studied. The absence
of a consistent compensatory change in the contralateral
limb suggests that the increase in stance time in the
affected limb is probably sufficient to stabilize rear loco-
motion under these test conditions.
Table 1 Effect of hyaluronan injection on the mean normalized stance and propulsion times of affected limbs in
murine osteoarthritis model
a
Day 5 Day 12 Day 19
Measurement Mean
(±SD)
b
Student’s t-
test
Wilcoxon Mean
(±SD)
b
Student’s t-
test
Wilcoxon Mean
(±SD)
b
Student’s t-
test
Wilcoxon
Stance
OA (n = 14) 1.18 (0.24) 0.009 0.014 1.40 (0.47) 0.004 0.0001 1.43 (0.40) 0.0004 0.012
OA + HA
(n = 14)
1.05 (0.19) 0.48 0.39 1.10 (0.21) 0.19 0.12 0.99 (0.17) 0.89 0.84
OA + saline
(n =8 )
1.29 (0.14)
c 0.0001 N.S. 1.24 (0.26) 0.002 0.004 1.32 (0.30) 0.01 0.04
Propulsion
OA (n = 14) 1.46 (0.43) 0.0005 0.002 1.28 (0.43) 0.025 0.024 1.61 (0.56) 0.0005 0.042
OA + HA
(n = 14)
1.19 (0.31) 0.11 0.15 1.26 (0.36) 0.06 0.13 0.94 (0.36) 0.66 N.S.
OA + saline
(n =8 )
1.78 (0.14)
c 0.0006 N.S. 1.16 (0.43) 0.11 0.15 1.55 (0.18) 0.0001 0.008
aSD, standard deviation; OA, osteoarthritis; HA, hyaluronan; N.S., P value outside the range of Wilcoxon probability tables;
bdata represent the means (±SD) (n
values provided in left column) of the normalized stance and propulsion times for each experimental group on each day. The value for each gait parameteri n
each hindlimb of each mouse was normalized to the corresponding pretreatment value for that mouse;
cn = 4 mice for this experimental group. Values under
Student’s t-test and Wilcoxon rank-sum test headings are P values for the statistical significance of the difference between the means and unity.
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but only HA is effective for prolonged periods
Since measurement of mechanical allodynia by the von
Frey test has been used to monitor pain sensation dur-
ing disease progression in the DMM (destabilization of
the medial meniscus) model of murine OA [21], the
method was also applied in this study with the nonsur-
gical model. The von Frey test determines a threshold
score (expressed in grams) at which the mouse with-
draws its paw from contact with a fine filament, so that
the lower the score the more sensitive or painful is the
paw or limb. Baseline analyses for untreated mice (n =
6) gave a mean value (±SD) of 0.95 ± 0.08 g for both
hindpaws. Measurements of the treadmill-only mice
taken on days 5 and 19 (Figure 3a) showed no difference
from this baseline value or from the mean of their own
pretreatment values, showing that treadmill running
alone for up to 14 days does not generate mechanical
allodynia in the hindpaws.
Measurements for allodynia in both limbs of mice
from the three treated groups (OA, OA + HA and OA
+ saline) at days 5, 12 and 19 are shown in Figure 3b.
For the OA group at day 5, the mean allodynia score in
the injected limbs was approximately 0.35 g, which
represents a major increase in allodynia, and this score
was maintained up to day 19. The OA + HA group
exhibited a significant reduction (P < 0.0001) in allody-
nia (increase in gram value) relative to the OA group at
days 5, 12 and 19. The OA + saline group also exhibited
a significant reduction (P < 0.0001) at all times, showing
that for this measurement, at least part of the effect of
HA appears to be due simply to the dilution of the joint
fluids. However, when the same data were analyzed in
terms of differences from baseline scores, the OA + HA
group showed normalization (that is, the difference
between mean score and mean baseline score was not
significant) at days 5 and 19 and a trend to normaliza-
tion on day 12. However the OA + saline group did not
exhibit such normalization at any time. The greater pro-
tective effect of HA relative to saline on allodynia in the
OA limb was most evident at day 19. At this time, allo-
dynia in the OA + HA group was markedly reduced
relative to the OA group (P <0 . 0 0 0 1 ) .A l l o d y n i af o rt h e
OA + saline group was also reduced relative to the OA
group, but the reduction was minor relative to the HA
effect, and a return to baseline levels did not occur at
any time.
Finally, the contralateral limbs of animals in the OA
group and the OA + saline group showed significantly
increased allodynia relative to baseline (P < 0.006 and P
< 0.05, respectively) at day 5 (Figure 3b). This increase
did not occur, however, in the OA + HA group, show-
ing that at this early time, only HA had a protective
effect against allodynia in both OA and contralateral
limbs. In addition, the increased allodynia in the contral-
ateral limbs was not accompanied by any change in gait
parameters.
Intraarticular HA, but not saline, protects against cartilage
erosion and fibrosis in murine OA
Macroscopic evaluation of cartilage surfaces in OA
joints at day 19 (Figure 4, top) showed that erosion (Fig-
ure 4, top) had progressed markedly on the posterior
aspects of the lateral and medial tibial plateaus, the
medial aspect of the anterior femoral condyles and the
distal regions of the patellar grooves. In treadmill-only
Table 2 Effect of hyaluronan injection on the mean of normalized stance and propulsion times of contralateral limb in
murine osteoarthritis model
Day 5 Day 12 Day 19
Measurement Mean
(±SD)
b
Student’s t-
test
Wilcoxon Mean
(±SD)
b
Student’s t-
test
Wilcoxon Mean
(±SD)
b
Student’s t-
test
Wilcoxon
Stance
OA (n = 14) 1.10 (0.34) 0.29 0.52 1.16 (0.29) 0.051 0.078 1.03 (0.13) 0.51 0.54
OA + HA
(n = 14)
0.95 (0.15) 0.34 N.S. 1.10 (0.20) 0.15 0.080 1.10 (0.20) 0.15 0.080
OA + saline
(n =8 )
0.97 (0.06)
c 0.23 N.S. 1.23 (0.26) 0.026 0.046 1.21 (0.26) 0.04 0.12
Propulsion
OA (n = 14) 0.92 (0.41) 0.48 N.S. 1.11 (0.42) 0.34 0.35 1.16 (0.46) 0.21 0.34
OA + HA
(n = 14)
0.80 (0.21) 0.016 0.018 1.01 (0.19) 0.87 0.80 0.97 (0.20) 0.68 N.S.
OA + saline
(n =8 )
0.78 (0.25)
c 0.02 N.S. 1.05 (0.14) 0.30 0.50 1.17 (0.52) 0.36 0.69
aSD, standard deviation; OA, osteoarthritis; HA, hyaluronan; N.S., P value outside the range of Wilcoxon’s probability tables;
bdata) represent the means (±SD) (n
values provided in left column) of the normalized stance and propulsion times for each experimental group on each day. The value for each gait parameteri n
each hindlimb of each mouse was normalized to the corresponding pretreatment value for that mouse;
cn = 4 mice for this experimental group. Values under
Student’s t-test and Wilcoxon rank-sum test headings are P values for the statistical significance of the difference between the means and unity.
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erosion. In the OA joints, erosion sites were always adja-
cent to visible periarticular fibrotic deposits (Figure 4,
top). Injection of HA (Figure 4, OA + HA) resulted in
marked protection against cartilage erosion on the
femoral and patellar groove locations, and periarticular
fibrosis was diminished at all sites. In contrast, saline
injection (Figure 4, OA + saline) provided only minor
protection from both cartilage erosion and fibrosis. To
provide quantitative comparisons, erosion and fibrosis
scores were calculated for mice (n = 8) in each of the
three groups (Figure 5). This showed that HA injection
provided marked protection from femoral erosion (P =
0.04) but was ineffective in protecting mice from tibial
plateau erosions. However, fibrotic deposits at all sites
were markedly diminished in the OA + HA group (Fig-
ure 5b; P values shown in figure) relative to the OA
group.
To further characterize the macroscopic differences in
tissue erosion and remodeling among the four groups,
sagittal histologic sections from sites known to be
involved (medial femoral condyle and patellar groove)
were stained with Safranin O. Typical images (selected
from n = 5 mice per group) for the treadmill-only and
the OA groups are shown in Figure 6. Equivalent images
for the OA + HA and OA + saline groups are shown in
Figure 7. For each experimental group, two regions of
the condyle and two regions of the groove are shown in
both low-power fields (4-fold magnification, ) and high-
power fields (20-fold magnification,). Treadmill-only
femoral condyles (Figures 6a through 6f) showed intact
cartilage on the central region of the condyle and the
adjacent groove, as well as intact cartilage at the distal
and proximal ends of the groove. OA femoral condyles
(Figures 6g through 6l) had severe cartilage loss (down
to the subchondral bone) on both the femoral condyle
and patellar groove areas. In addition, fibrous tissue
with underlying chondrophytes was detected adjacent to
cartilage erosion on the anterior aspects of the medial
femoral condyles (Figure 6i) and on the patellar groove
(Figure 6l) in four of the five OA specimens examined.
Stained sections from the OA + HA group (Figures 7a
Figure 3 Mechanical allodynia measurements with von Frey filaments of mice in each of the four experimental groups. Panel (a) shows
the mean 50% withdrawal threshold value (in grams) for the treadmill only mice at pretreatment, day 5 and day 19. Panel (b) shows the
equivalent data for both injected and contralateral limbs (n = 5 to 8 per group) of mice at 5, 12 and 19 days post-injury. (see symbol box for
group identification). p values (Student’s t-test) are given above data sets which are statistically significantly different from the osteoarthritis (OA)
group on the same day.
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Page 7 of 14Figure 4 The macroscopic appearance of cartilage and surrounding tissues from murine knee joints. To illustrate typical cartilage erosion
(E) and periarticular fibrosis (F), tibial, femoral and patellar groove images (original magnification, × 32) are shown for each of the experimental
groups (osteoarthritis (OA), OA + hyaluronan (HA), OA + saline and treadmill-only) at age day 19. TP, tibial plateau; FC, femoral condyle; PG,
patellar groove.
Figure 5 Joint Tissue Pathology Scores showing the protective effects of prophylactic hyaluronan (HA) on murine joint osteoarthritis
(OA). (a) Cartilage erosion scores and (b) fibrosis scores for the OA (n = 8) and OA + HA (n = 8) groups illustrates the statistically significant and
area-specific effects of HA on murine OA pathology. See Materials and methods section for details on scoring.
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protection seen macroscopically on the femoral condyle
and the patellar groove. By comparison, the OA + saline
group (Figures 7g through 7l) exhibited some protection
against cartilage erosion and fibrous or chondrophytic
remodeling in both the groove area and the posterior
medial condyle, but showed no prevention of cartilage
erosion on the anterior medial condyle (Figure 7l).
To further illustrate the fibrotic tissue changes in the
periarticular regions of the joint, sections of the lateral
tibial plateaus from treadmill-only and OA joints were
also stained with Safranin O (Figures 8a and 8c) or anti-
bodies to type I collagen (Figures 8b and 8d). In tread-
mill-only mice, the tibial plateaus (Figure 8a) showed
normal morphologies for articular and growth plate car-
tilages and periosteal membrane. Staining of an adjacent
section for type I collagen (Figure 8b) showed it to be
abundant in the cells and matrix of the periosteum.
Type I collagen was also clearly detected in cells
throughout the depth of the articular cartilage, illustrat-
ing the phenotypic plasticity of the chondrocyte popula-
tion in 12- to 15 week-old C57Bl/6 male mice.
Representative images of the OA group samples (Figures
8c and 8d) illustrate extensive loss of tibial plateau carti-
lage and its replacement by type I collagen-positive,
Safranin O-negative fibrous ingrowths (black arrows in
Figures 8c and 8d). Moreover, these ingrowths appeared
to be continuous with the periosteum and synovial
Figure 6 The effect of experimental osteoarthritis (OA) on Safranin O histological staining of the murine knee joint. Typical sections
from the condyle and groove areas of (a through f) the treadmill-only group and (g through l) the OA group are shown. In each case, the
boxed areas are shown at high magnification to the immediate right; for example, the boxed areas in (a) are shown at higher magnification in
(b) and (c). Black arrows indicate (h and k) cartilage erosion and (i and l) fibrotic or chondrophytic deposits.
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Page 9 of 14lining (black stars in Figures 8c and 8d). Since such
fibrotic remodeling was essentially prevented by HA
injection (Figures 4, 5 and 7), it seems likely that HA
prevents activation of pathways that result in prolifera-
tion, migration and fibrotic differentiation of periosteal
and synovial cells in this murine model of OA.
Discussion
The data presented here (Figures 4, 5, 7 and 8) support
the results of previous studies on experimental OA in
rabbits and dogs showing that intraarticular HA can
suppress synovial hyperplasia [10] and fibroblastic
encroachment onto the articular surface [11] while pro-
tecting against cartilage erosion [26,27]. These therapeu-
tic effects appear to be independent of the polymeric
structure of HA, since the work described here was
done with a cross-linked bacterial HA, whereas in other
studies [8-10] non-cross-linked, high-molecular-weight
preparations were found to be effective. The results of
the histopathology in the current study suggest that HA
blocks the ingress of activated periosteal and synovial
cells and also protects against the loss of cells and
matrix from femoral and patellar groove cartilages.
While the precise mode of action of HA on these cells
is unknown, our studies in the TTR and DMM models
of OA have shown that ablation of Adamts5, prevents
both cartilage erosion and fibrotic remodeling in chal-
lenged joints [20], just like HA injection in the TTR
model. Since ADAMTS5 protein has been isolated in a
complex with HA from both human OA cartilage [28]
Figure 7 The effect of intraarticular hyaluronan (HA) or saline on Safranin O histological staining of the osteoarthritis (OA) knee joint.
Typical sections from the condyle and groove areas of (a through f) the OA + HA group and (g through l) the OA + saline group are shown.
In each case, the boxed areas are shown at high magnification to the immediate right. (h, i and l) Black arrows indicate cartilage loss.
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that injected HA may act primarily by blocking
ADAMTS5-mediated activation of profibrotic pathways
in periarticular cells.
In this regard, the current findings should provide a
new framework for mechanistic studies on the effects of
HA injection on OA pathology. This will be facilitated
by the availability of a range of genetically modified
mice in which HA-responsive components of well-estab-
lished cellular pathways have been modified. For exam-
ple, studies with knockout mice lacking HA-binding
receptors, such as CD44 and RHAMM (receptor for
hyaluronan-mediated motility) or Toll-like receptors 2
and 4, might illuminate the mechanism by which
injected HA is retained in or near the joint space. Thus
binding of exogenously delivered HA to such receptors
might abrogate cell stress responses to joint injury, pro-
cesses which might otherwise result in inflammation,
cytokine release and accelerated tissue destruction
[30-32].
Meta-analyses of clinical trials [3] have concluded that
HA injection in humans has a real but modest effect
over placebo on subjective patient pain measures. In the
present work, we have used von Frey filaments to exam-
ine the potential pain-relieving effects of HA (or saline)
injected during the early inflammatory phase. The most
notable finding was that HA was superior to saline with
regard to pain relief, but there was a marked difference
only on day 19 of the model, when joint lesions were
most advanced. This suggests that pain relief by HA
injection includes both short-lived and longer-lived
mechanisms. The short-lived effects appear to operate
l a r g e l yb yd i l u t i o no ft h ej o i n tf l u i d ,w h e r e a st h el o n g -
lived effects are probably specific to HA and may
require its direct or indirect blockade of pain receptors
[33]. The finding that HA, but not saline, injection
eliminated the transient allodynia in the contralateral
limb suggests that it may sequester factors which would
otherwise enter the circulation. In this regard, Gomis et
al. [33] suggested that HA reduces joint nociceptor
activity in part because of its rheological properties but
also by binding inflammatory mediators present in the
joint tissues.
Probably the major contribution of the present work is
the development and validation of gait analysis as an
important tool in the evaluation of murine models of
OA. In essence, we have shown that experimental mur-
ine OA is accompanied by no change in stride time but
ac o n s i s t e n ti n c r e a s ei np e r c e n t a g es t a n c et i m e( a n
increase from approximately 48% to about 75% in the
present model) when measured at 18 cm/second on a
17° uphill gradient. Importantly, the magnitude of the
percentage stance changes associated with this OA
model is sufficient to readily examine the effects of ther-
apeutic interventions. Further, the same OA mice exhib-
ited a prolonged enhancement in mechanical allodynia
Figure 8 Fibrotic tissue changes around the lateral tibial plateau associated with experimental murine osteoarthritis (OA).T y p i c a l
sections from (a and b) the treadmill-only group and (c and d) the OA group are shown stained with (a and c) Safranin O or (b and d)
antibodies to type I collagen. Black arrows indicate Safranin O-deficient tissue populated with collagen type I-positive cells (c and d),
respectively. PO, periosteum; GP, growth plate; TP, tibial plateau; SY, synovium.
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monitored.
Notably, an association of OA joint damage and
increased percentage stance time (at a standard velocity)
was also recently reported in a study using 9-month-old
type IX collagen-deficient (Col9
-/-)m i c e[ 3 4 ] .T h e
authors suggested as a possible mechanism for the
increased stance time in this spontaneous OA model
that the knockout mice adapted with an altered locomo-
tion pattern (increased percentage stance time) to
potentially reduce peak joint forces and thus protect the
hindlimbs during walking. This idea is supported by the
finding that a reduction in peak force across the normal
mouse knee occurs as the total stance time increases
[35].
The process that results in the increased percentage
stance time in the present murine OA model remains to
be investigated. An important clue may be provided by
the observation that the maximum increase in percen-
tage stance time (about 27% on day 19) was already
increased by about 10% on day 5, which is before the
start of treadmill running (see Figure 2 and Table 1).
This indicates that the gait change can be initiated by
TGFb1 injection alone; however, it is not further
increased or maintained in the absence of treadmill
challenge (data not shown). It therefore may result from
a loss of knee laxity due to the accompanying fibrosis of
the soft tissues. Alternatively, inflammation and func-
tional impairment in the biceps femorus, which lifts the
lower hindleg during swing phase and stabilizes it dur-
ing stance [36] might be a contributing factor.
Further mechanistic insight is provided by the finding
in a previous study [37] that in collagen-induced inflam-
matory ankle arthritis, severe disease is accompanied by
a decrease in stride time (due to decreases in both
stance and swing times), a decrease in stride length and
an increase in stride frequency (speed set at 15 cm/sec-
ond). In another study [38], it was found that induction
of OA by interleukin 1b injection into rat knees resulted
in an asymmetric gait (measured at constant speed) in
which the percentage stance time in the affected limb
was reduced relative to the contralateral limb. The gen-
eral finding that gait adaptations measured at constant
speed are very different in ankle inflammation [37], knee
inflammation [38] and knee injury (present study) illus-
trates the discriminatory power of gait analysis for dif-
ferent forms, stages and severities of murine arthritis. In
this regard, the establishment of standardized proce-
dures [39] for the evaluation of gait parameters in mur-
ine OA models should be added to existing methods,
such as whole joint macroscopic pathology ([22] and
present study), confocal laser-scanning microscopy [40]
and histopathology [41].
Finally, it appears that the current murine study has
clear clinical relevance, since human OA is also accom-
panied by increases in percentage stance time [42,43]. In
this case, the increase results directly from the fact that
during voluntary locomotion, OA patients walk more
slowly than normal controls [44]. This does not, of
course, exclude the possibility that OA patients have a
higher percentage stance time than normal individuals
at the same walking speed. In either case, it is clear that
OA patients adapt to achieve walking conditions which
increase percentage stance time and thereby stabilize
the affected limb; however, in patients with symptomatic
OA, this strategy is accompanied by higher than normal
peak loading and higher than normal loading through-
out stance time [45]. In this regard, the current murine
model appears to accurately mimic the gait adaptations
seen in human OA, although it is unknown whether the
increased percentage stance time in murine OA is
accompanied by higher or lower peak loading and load-
ing throughout stance time. Whether HA therapy in
human OA is accompanied by a change in walking
speed and/or a reduction in percentage stance time also
remains to be determined.
Conclusions
In the present study, we have shown that a single injec-
tion of HA ameliorates both gait changes and the loca-
tion-specific tissue destruction seen in the unilateral TTR
murine model of OA. These findings are consistent with
the conclusion that the gait change itself (that is, a major
increase in percentage stance time), while apparently a
protective response, may in fact be responsible for
exacerbating the biomechanical and cellular biological
processes which are responsible for disease progression.
We also conclude that gait analysis represents a valu-
able addition to the methods currently used for evalua-
tion of the severity of joint changes in murine arthritis
models. Gait analysis is particularly useful because it can
provide multiple, objective, quantitative readouts on all
limbs of individual mice throughout the time course of
an experiment. When used in conjunction with geneti-
cally modified mice, gait analysis has a unique potential
to provide mechanistic information on the relationship
between locomotion and the tissue damage pathways of
OA initiation and progression.
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